Answers are grounded in this paper and cite their sources.
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a prevalent, steadily increasing metabolic liver disease characterized by steatosis and liver injury, with disease progression influenced by environmental risk factors. Cadmium (Cd), a ubiquitous environmental metal toxicant, has been epidemiologically associated with MASLD progression. Although mitochondrial dysfunction and oxidative lipid damage contribute to MASLD pathogenesis, whether and how Cd disrupts mitochondrial lipid homeostasis to initiate lipid peroxidation-associated injury remains elusive. In this study, we demonstrate that cardiolipin (CL) oxidation-associated ferroptosis and hepatic lipid accumulation are markedly increased in Cd-exposed mouse livers in vivo and in Cd-treated hepatocytes in vitro, exacerbating liver injury and promoting MASLD progression. Integrated transcriptomic, metabolomic, and lipidomic analyses revealed profound alterations in mitochondrial lipid metabolic pathways, highlighting CL remodeling as a key regulatory layer underlying oxidative lipid damage and ferroptosis-associated liver injury. Mechanistically, phosphoglycerate mutase family member 5 (PGAM5) functions as an upstream regulator. Cd exposure enhances mitochondrial PGAM5–lysocardiolipin acyltransferase 1 (LCLAT1) interaction, triggering PGAM5-dependent LCLAT1 dephosphorylation at serine 410 (S410), thereby reinforcing LCLAT1 mitochondrial translocation, accelerating CL acyl-chain remodeling, and driving CL oxidation-dependent ferroptosis. Pharmacological or genetic PGAM5 inhibition attenuated CL oxidation, ferroptosis, and MASLD-like liver injury in vitro and in vivo. Moreover, PGAM5 and LCLAT1 are upregulated and positively correlated in human MASLD livers. Collectively, these findings define a PGAM5–LCLAT1–CL axis linking cadmium exposure to mitochondria-driven ferroptosis and MASLD progression, and identify PGAM5 as a potential therapeutic target for environmentally associated MASLD.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: